KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Non-Current Liabilities: 2019-2024

Historic Total Non-Current Liabilities for Royalty Pharma (RPRX) over the last 4 years, with Dec 2024 value amounting to $7.9 billion.

  • Royalty Pharma's Total Non-Current Liabilities rose 18.58% to $9.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 billion, marking a year-over-year increase of 18.58%. This contributed to the annual value of $7.9 billion for FY2024, which is 24.96% up from last year.
  • Latest data reveals that Royalty Pharma reported Total Non-Current Liabilities of $7.9 billion as of FY2024, which was up 24.96% from $6.3 billion recorded in FY2023.
  • Royalty Pharma's Total Non-Current Liabilities' 5-year high stood at $7.9 billion during FY2024, with a 5-year trough of $6.3 billion in FY2023.
  • Over the past 3 years, Royalty Pharma's median Total Non-Current Liabilities value was $7.3 billion (recorded in 2022), while the average stood at $7.2 billion.
  • As far as peak fluctuations go, Royalty Pharma's Total Non-Current Liabilities declined by 13.57% in 2023, and later climbed by 24.96% in 2024.
  • Over the past 3 years, Royalty Pharma's Total Non-Current Liabilities (Yearly) stood at $7.3 billion in 2022, then fell by 13.57% to $6.3 billion in 2023, then rose by 24.96% to $7.9 billion in 2024.